Healthcare Glenmark shares down 7%; market gets realistic about Fabiflu impact on earnings Updated : June 23, 2020 03:47 PM IST Glenmark Pharma shares were down over 7 percent during Tuesday's trading session. Analysts were surprised at Monday's rally and said that the potential earnings from the sale of Fabiflu did not warrant such a big gain in the stock price. Subscribe to Moneycontrol PRO at just Rs.33/- per month for the first year. Use code SUPERPRO. Limited period offer. Available on Web and Android.